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Background: Warm ischemia-reperfusion injury related to donation after cardiac 
death is a crucial issue in transplantation. Since surfactant function deteriorates in 
lungs during warm ischemia, we hypothesized prerecovery surfactant inhalation 
would mitigate warm ischemia-reperfusion injury. 
Methods: We rendered donor dogs cardiac dead and left them at room temperature. 
All animals received ventilation for 60 min starting at 240 min after cardiac arrest. 
The animals were divided into 2 groups: NS (Normal saline) and SF (Surfactant). 
The NS group (n = 7) and SF group (n = 5) received aerosolized normal saline and 
aerosolized surfactant, respectively. The lungs were flushed, procured, and then the 
left lung was transplanted into recipient dogs. At 45 min of reperfusion, the right 
pulmonary artery was ligated, and the left transplanted lung function was 
evaluated. 
Results: In the NS group, 2 of 7 died at 75 min after reperfusion, whereas all 5 
animals in the SF group survived for 240 min after reperfusion. The SF group 
showed significantly better dynamic compliance, oxygenation, and wet-to-dry 
weight ratio. Furthermore, the SF group had higher levels of high-energy 
phosphates in the lung tissues and lower levels of IL-8, TNF-α, and protein in the 
bronchoalveolar lavage fluid. Histologically, the lungs in the SF group showed fewer 
signs of interstitial edema and hemorrhage and significantly less neutrophilic 
sequestration than those of the NS group. 
Conclusions: Our results indicated prerecovery surfactant inhalation improved 
graft function, maintained adenine nucleotide levels, and prevented 






To deal with the shortage of donor organs in lung transplantation, donation after 
cardiac death (DCD) has been introduced worldwide as one of the potential 
strategies to increase the donor pool. Steen et al. first successfully performed lung 
transplantation from uncontrolled DCD donors in 2000.1 Since then, several 
programs have reported acceptable outcomes comparable to donation after brain 
death.2,3 However, there has been a progressive increase in the number of patients 
on the waiting list, which continually exceeds the number of available organs. 
Warm ischemia inevitably occurs in DCD donors after cardiac arrest and may 
cause ischemia-reperfusion (I-R) injury after transplantation. The acceptable period 
of warm ischemia is short,4 thus limiting the frequency of lung transplantation from 
uncontrolled DCD donors. Therefore, the inhibition of warm I-R injury is crucial to 
facilitating lung transplantation from uncontrolled DCD donors.5 
In DCD donors, intravenous drug administration is difficult, since the 
circulation has stopped. However, inhalation appears to be not only suitable and 
convenient for drug administration but offers a lung-specific drug delivery route.6,7 
Moreover, our previous experiments using drug inhalation in warm 
ischemic-reperfused rat lungs have been successful.6,7 
A pulmonary surfactant mostly comprises phospholipids and surfactant 
proteins (SP-A, -B, -C, and -D), and forms a monolayer at the air-lipid interface, 
reducing the surface tension in the alveoli. This mechanism prevents alveolar 
collapse8,9 and protects the lung. 
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Although surfactants have been used as a therapy for ARDS, exogenous 
surfactant might improve oxygenation but did not improve mortality in most 
reports.10-12 Davidson et al. stated the potential explanation: patients with ARDS 
usually die of multi-organ system failure from their underlying disease process 
rather than from respiratory failure per se: the proper ‘surfactant recipe’ had not 
yet been found, that is, a dose, formulation, and delivery strategy of surfactant that 
could be effective.11 Thus, surfactant administration for ALI and ARDS has not been 
established as a standard therapy. 
Surfactants have been administered in clinical settings to patients with severe 
primary graft dysfunction after transplantation13,14 and for donor lungs.15 Recently, 
surfactant function was reported to deteriorate with increasing warm ischemic time 
intervals9; however, to date, no study has been conducted on the protective effect of 
surfactant administration against pulmonary warm I-R injury. Therefore, we 
examined the protective effect of surfactant administration in marginal donor grafts 
from uncontrolled DCD donors in a canine lung transplantation model. 
 
Materials and Methods 
Animals 
Twelve pairs of weight-matched TOYO Beagles (9.75–11.05 kg, Kitayama Labes Co. 
Ltd., Hongo Farm, Yamaguchi, Japan) were used in this study. All animals received 
humane care in compliance with the Principles of Laboratory Animal Care, which 
was formulated by the National Society for Medical Research, and the Guide for the 
Care and Use of Laboratory Animals, prepared by the Institute of Laboratory 
Animal Resources and published by the National Institutes of Health (NIH 
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publication no. 86-23, revised 1996). The study protocol was approved by the ethics 
committee of the Graduate School of Medicine at Kyoto University, Japan. 
 
Surfactant and Aerosol Delivery 
In this study, we used beractant (Surfacten®, Mitsubishi Tanabe Pharma 
Corporation, Osaka, Japan). Beractant is a natural bovine lung extract containing 
phospholipids, neutral lipids, fatty acids, and the 2 surfactant-associated proteins 
SP-B and SP-C. A 30-mg/mL surfactant solution was obtained by dissolving 
Surfacten® with normal saline (0.9%). The surfactant was aerosolized by a 
nebulizer (AGAL1000, Aerogen, Ireland) and placed in the inspiratory loop of the 
ventilator. In this system, the diameters of ~90% and ~60% of the aerosolized 
particles were maintained below 10  and 3.0 m, respectively. 
 
Donor Preparation 
The operative technique was previously reported.16 Donor dogs were anesthetized 
by an intramuscular injection of midazolam (0.5 mg/kg), xylazine (0.25 mg/kg), and 
atropine sulfate (0.05 mg/kg). The animals were then intubated and mechanically 
ventilated at a tidal volume of 25 mL/kg and a respiration rate of 15 breaths/min. 
The positive end-expiratory pressure was 5.0 cmH2O; the inspired O2 fraction was 
1.0. The donors were maintained at an inhalation of 1% to 2% sevoflurane and an 
intravenous injection of vecuronium bromide (0.4 mg/kg/hr). They were euthanized 
by an intravenous administration of potassium chloride (0.5 mEq/kg), without 
heparinization. The ventilators were removed, and the tracheal tubes were open to 
room air. All donors were left at room temperature (21°C) for 240 min and 
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subsequently received ventilation with 100% oxygen for 60 min starting at 240 min 
after cardiac arrest. The animals were divided into a NS (Normal saline) group and 
a SF (Surfactant) group. During this ventilation period, the NS group (n = 7) 
received 8 mL of aerosolized normal saline, while the SF group (n = 5) received 
aerosolized surfactant: 240 mg of surfactant dissolved in 8 mL of normal saline was 
loaded. A pulmonary arterial flush was performed on all donors at 300 min after the 
cardiac arrest, using ET-Kyoto solution (Otsuka Pharmaceutical Factory Inc., 
Tokushima, Japan), an extracellular preservation solution that we originally 
developed for clinical lung transplantation.17 For the antegrade flush, we used 100 
mL/kg of this solution; 50 mL/kg was used for the retrograde flush (temperature 
4°C; pressure, 30 cmH2O). Ventilation was performed during the flush. The 
recovered organs, semi-inflated with 100% oxygen, were preserved at 4°C for 2 
hours. 
 
Recipient Preparation and Transplantation 
Recipient dogs were anesthetized, maintained, and ventilated in the same manner 
as the donors. Peak inspiratory pressure was monitored by a pressure transducer 
attached to the tracheal tube. For each recipient, a 5-F thermodilution catheter (151 
F7, Edwards Lifesciences, Irvine, CA) was placed in the main pulmonary artery 
from the right femoral vein to measure pulmonary arterial pressure, central venous 
pressure, and cardiac output. A femoral arterial line was inserted for measuring 
arterial pressure and for arterial blood gas analysis. We then performed a left 
pneumonectomy and left lung transplantation. We set 60 min for the implantation 
time. After reperfusion, a 2.0-mm catheter was inserted directly into the left atrium 
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for monitoring left arterial pressure. The right pulmonary artery was encircled with 
vascular tape and clamped with a tourniquet at 45 min after reperfusion to evaluate 
the function of the transplanted left lung. After the right pulmonary artery was 
clamped, the right main bronchus was also encircled with vascular tape and 
intermittently clamped to evaluate the pulmonary dynamic compliance of the 
transplanted left lung. 
 
Physiological Data Analysis 
The pulmonary shunt fraction (Qs/Qt (%)) was calculated according to the following 
formula: Qs/Qt (%) = (Cc–Ca)/(Cc–Cv)×100, where Cc, Ca, and Cv represent the 
oxygen content of the pulmonary capillary, artery, and venous blood, respectively. 
The pulmonary dynamic compliance (mL/cmH2O) was defined as tidal volume/[peak 
airway pressure − positive end-expiratory pressure]. The pulmonary dynamic 
compliance of the transplanted left lung was defined as half of the tidal 
volume/[peak airway pressure − positive end-expiratory pressure]. Arterial and 
pulmonary arterial blood samples were taken to analyze blood gases with a blood 
gas analyzer (iSTAT Portable Clinical Analyzer; iSTAT Corp., East Windsor, NJ). 
 
Wet-to-Dry Weight Ratio (WDR) 
Left lung tissues (1000–2000 mg) were used to calculate the WDR at 240 min after 
reperfusion or at death. The tissues were excised from the tip of the ventral side of 
the lung, and the cut end was closed by ligation. The wet weight (mg) was measured 
first; the dry weight (mg) was measured after the tissue had been dried overnight at 




Bronchoalveolar Lavage (BAL) 
After the collections for the other investigations had been conducted, the lavage of 
the transplanted left lung was performed via fiberoptic bronchoscopy with 30 mL of 
normal saline. Recovery was approximately 15 mL in all experiments. The lavage 
was centrifuged, and the supernatant was stored −80°C until measurements. 
 
Measurement of Adenine Nucleotide Levels 
We used the pieces of peripheral lung tissues collected from donors before and after 
inhalation and from recipients at 240 min after reperfusion. We measured lung 
tissue levels of ATP, ADP, AMP, and total adenosine nucleotides (TAN; TAN = ATP 
+ ADP + AMP) using high-performance liquid chromatography (Shim-pack 
CLC-ODS column; 15 cm × 6.0 mm; Shimadzu, Japan). 
 
Cytokine Levels in BAL Fluid 
We used IL-6, IL-8, and TNF-α enzyme-linked immunosorbent assays (ELISAs) kits 
(Quantikine, R&D Systems Inc., Minneapolis, MN) to measure the respective levels 
of these proteins in BAL fluid at 4 hours after reperfusion. 
 
BAL Protein Levels 
Protein concentrations in 10 L of BAL was determined by a protein assay (Bio-Rad 
Laboratories, Hercules, CA, USA) with bovine serum albumin as a standard. 
 
Myeloperoxidase (MPO) Activity 
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The level of MPO was measured in the left lung of each of the studied lungs, which 
were collected at 240 min after reperfusion and snap frozen in liquid nitrogen until 
the assays were performed. MPO activity ( U/mg wet weight; U = mol/min) was 
measured with an MPO Assay Kit (BioVision Research Products, Mountain View, 
CA, USA), according to the manufacturer’s instructions, and defined as the sample 
measurement / [incubation time × sample volume]. 
 
Macroscopic Figures and Histology 
We recorded the macroscopic appearances of the left lungs 4 hours after reperfusion. 
Left lung specimens obtained 240 min after reperfusion were used for histologic 
analysis. Each lung was immersed in 10% formalin, embedded in paraffin, and 
stained with hematoxylin-eosin (H-E). 
 
Statistical Analyses 
All statistical analyses were performed using STATVIEW v5.0 (Abacus Concepts 
Inc., Berkeley, CA). Values are expressed as the mean ± the standard deviation. We 
used Mann-Whitney U tests and repeated-measures analysis of variance tests to 
explore differences between and within treatment groups. Significance was defined 
as a p value less than 0.05. 
 
Results 
No significant differences were observed between the 2 experimental groups in 
terms of the donor or recipient weights (NS group vs. SF group, donor weight: 10.2 ± 
0.3 kg vs. 10.5 ± 0.3 kg; recipient weight: 9.2 ± 0.4 kg vs. 9.4 ± 0.4 kg). We were able 
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to perform the implantation within 60 min. All 5 animals in the SF group survived 
until the endpoint of the study (240 min after reperfusion), whereas only 5 of 7 in 
the NS group survived. Two animals died of graft dysfunction at 75 min after 
reperfusion. 
 
Assessment of Pulmonary and Cardiac Function 
In both groups, the dynamic compliance of the donor’s bilateral lungs was compared 
before and after inhalation by the paired t-test. In the NS group, no differences were 
observed before and after inhalation (18.4 ± 6.2 and 18.7 ± 5.9 ml/cmH2O, 
respectively; p = 0.69). However, in the SF group, the dynamic compliance was 
significantly higher after inhalation (before inhalation vs. after inhalation: 16.9 ± 
3.7 vs. 25.0 ± 5.3, respectively; p = 0.0055). Moreover, the dynamic compliance of the 
recipient’s bilateral lungs in the SF group was higher just prior to reperfusion, with 
this difference reaching significance (p = 0.0003; Table 1). The dynamic compliance 
of the recipient’s transplanted left lung in the SF group was also higher after 
clamping of the right pulmonary artery, and this difference also reached 
significance (p = 0.031). The PaO2 at 240 min after reperfusion was significantly 
lower in the NS group (64.0 ± 15.0 mmHg) than that in the SF group (547.8 ± 96.2 
mmHg; p = 0.0022), while no difference in the PaCO2 was observed between the 2 
groups (p = 0.27). Furthermore, the shunt fraction and the differences in the 
alveolar-arterial oxygen pressure (A-aDO2) were significantly lower in the SF group 
than those in the NS group (p = 0.0078 and p = 0.0017, respectively). The 
pulmonary vascular resistance and the cardiac output seemed low and high, 
respectively, in the SF group; however, neither these of parameters nor the mean 
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The WDR at 240 min after reperfusion was significantly lower in the SF group than 
that in the NS group (6.34 ± 1.37 vs. 11.98 ± 3.27, respectively; p = 0.0090). 
 
Measurement of Adenine Nucleotide Levels 
Just after inhalation, the differences in the TAN, ATP, ADP, and AMP levels 
between the NS and SF groups did not reach significance (Figure 1A). However, at 
240 min after reperfusion in the SF group, the TAN and ATP levels increased, so 
that the TAN, ATP, and ADP levels were significantly higher than those in the NS 
group (TAN: p = 0.016, ATP: p = 0.016, ADP: p = 0.047; Figure 1B). 
 
Cytokine Levels in BAL fluid 
At 240 min after reperfusion, IL-8 and TNF-α levels in the BAL fluid were 
significantly lower in the SF group than those in the NS group (p = 0.0090 and 0.016, 
respectively; Figure 2A-C). 
 
Protein Concentration in BAL Fluid 
At 240 min after reperfusion, the protein concentration in BAL was significantly 
lower in the SF group than that in the NS group (NS group vs. SF group: 1.47 ± 0.50 





MPO activity has been previously used as a marker for neutrophilic sequestration 
during acute inflammatory responses.6 At 240 min after reperfusion, the MPO 
activity was lower in the SF group than that in the NS group (NS group vs. SF 
group: 30.0 ± 9.3 vs. 11.6 ± 7.2 U/mg wet weight; p = 0.0090). 
 
Macroscopic Figures and Histology 
At 240 min after reperfusion, lungs from animals in the NS group had broad 
dark-red areas that showed more patchiness than that observed macroscopically in 
the SF group (Figure 3A, B). Histologically, in the NS group, mild to severe 
interstitial and alveolar edema was observed in almost all areas; moreover, severe 
interstitial and alveolar hemorrhage was sporadically observed (Figure 4A). 




In this study, we used a canine lung transplantation model to investigate the effect 
of surfactant inhalation on I-R injury in lungs from DCD donors. Our results 
showed that surfactant inhalation in the last phase of warm ischemia improved 
graft functions, prevented protein leakage into alveoli, and maintained adenine 
nucleotide levels, thereby attenuating warm I-R injury in canine lungs. This is the 
first study to report that surfactant inhalation during warm ischemia attenuated 
warm I-R injury of the lung in a large animal model. 
Surfactant deficiency reduces the stability and patency of peripheral airways,18 
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leading to decreased lung compliance, atelectasis,19 and uneven distribution of 
inspired gas.20 In the current study, the dynamic compliance increased after 
surfactant inhalation in the SF group relative to that in the NS group. Further, the 
dynamic compliance was significantly higher in the SF group than that in the NS 
group and was maintained at a greater than baseline level until the end of the 
reperfusion period. Exogenous surfactant pretreatment reportedly improved lung 
compliance and gas exchange with beneficial results,21-23 consistent with our results. 
The surfactant treatment decreased the shunt fraction probably because of reduced 
microatelectasis and pulmonary edema, thereby leading to improved 
ventilation/perfusion mismatch with better oxygenation.24 In terms of PaCO2 values, 
there was no significant difference between the groups. This might be because the 
warm ischemic injury in the current study was not so severe as it affected a 
significant change in the value of PaCO2. Herein, we reconfirmed that prerecovery 
surfactant inhalation during warm ischemia could recondition graft compliance and 
ventilation inhomogeneity and thus lead to attenuation of I-R injury. 
The most important cellular role for oxygenation is ATP synthesis via the 
mitochondrial electron transport chain.25 ATP levels are reportedly considered 
useful indicators of reperfusion injury.26 In this study, the ATP levels at the end of 
reperfusion were similar to those just after inhalation; this maintenance might be 
one of the main causes of lung protection against I-R injury. 
IL-8 is a potent neutrophil chemotactic factor that promotes neutrophil 
adhesion, migration, and degranulation.27 Fisher et al. have shown that lung 
transplant patients who died from early lung dysfunction had significantly higher 
levels of IL-8 in the donor BAL.28 TNF-α is a proinflammatory cytokine secreted by a 
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number of cells, including macrophages, in response to a variety of stimuli.29 Serrick 
et al. have shown that BAL TNF-α levels significantly increased early after I-R 
injury.30 These observations were consistent with our results. Furthermore, 
surfactant has anti-inflammatory effects that are accompanied by decreased 
apoptosis during I-R injury.31 Neutrophilic sequestration greatly affects the 
vulnerability of the lung after I-R injury,32,33 and causes tissue damage by adhering 
to the vasculature, infiltrating local tissues, and releasing superoxides and 
elastases.33 In our study, surfactant inhalation prevented pulmonary edema, 
hemorrhage, and significantly reduced MPO activity. 
Less protein exudation into alveoli might reflect a reduced deterioration of the 
capillary-endothelial barrier.34 In this study, protein leakage in the NS group was 
significantly higher than that in the SF group; this result correlated to an 
improvement in the A-aDO2. Serum proteins have been shown to inhibit surfactant 
function, with this inhibition reportedly concentration dependent.35 Thus, massive 
protein leakage in the NS group could have deteriorated the surfactant function. 
Surfactants have been administered to patients with severe primary graft 
dysfunction13,14 and to donor lungs for the prevention of primary graft dysfunction.15 
Surfactant administration has been said to be relatively safe and non-invasive, but, 
its use in clinical lung transplantation is still rare owing to the high costs.15 In 
addition, surfactant inhalation has some adverse effects, such as transient 
desaturation during bronchoscopy for instillation.14 Therefore, standard protocols of 
surfactant therapy have not been established to date. Since the amount of 
surfactant preparation used in clinical lung transplantation was quite low 
compared with the use in ARDS,15 we investigated the surfactant therapy for lungs 
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donated after cardiac death. 
Although there are various types of merchandised surfactants available in the 
world, Surfacten® which we used in the current study is the only one that is 
powdered in storage and is resolved with solvents just before use. Thus, Surfacten® 
was shown to be active on use. Furthermore, neither antigenicity nor side effects 
have been reported when it is used within normal dose limits. 
The present study had several limitations. First, the cardiac arrest was induced 
by intravenous injection of potassium chloride, which was not performed in a 
clinical setting. We selected this procedure because cardiac arrest was induced 
uniformly. Second, as there was barely any agonal phase, we plan in the near future 
to use a setting in which cardiac arrest is induced by disconnection of the 
mechanical ventilation. 
In conclusion, we demonstrated that surfactant inhalation mitigated I-R injury 
on lungs donated after cardiac death in a canine lung transplantation model. 
Surfactant inhalation could be a convenient and effective method for improving 
graft functions in lung transplantation from DCD donors. 
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Lung tissue energy levels just after inhalation (A) and 240 min after reperfusion (B) 
in each group. TAN = ATP + ADP + AMP. ATP, adenosine triphosphate; ADP, 
adenosine diphosphate; AMP, adenosine monophosphate; TAN, total adenosine 
nucleotides. TAN: ※p = 0.016, ATP: ※p = 0.016, ADP: ※p = 0.047. 
 
Figure 2 
Cytokine levels in BAL fluid at 240 min after reperfusion in the NS and the SF 
groups (A-C). IL-8: ※※p = 0.0090, TNF-α: ※p = 0.016. 
 
Figure 3 
Macroscopic findings at 240 min after reperfusion in the NS (A) and SF (B) groups. 
 
Figure 4 
Histologic findings at 240 min after reperfusion (H-E staining). In the NS group, 
mild to severe interstitial and alveolar edema is observed in almost all areas, 
moreover, severe interstitial and alveolar hemorrhage is sporadically observed (A). 
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measures analysis of variance. 
Table 1.  Assessment of lung and cardiac function in surviving recipients in the NS (n = 5) and SF (n = 5) groups.  
    Time after transplantation, min 
 Before OP  30  75  120  180  240      P-value  
Dynamic compliance, bilateral lung, ml / cmH2O 
NS 23.6 ± 3.3  19.0 ± 1.6  13.7 ± 1.5  12.8 ± 1.9  12.8 ± 1.0  11.8 ± 1.5  
SF 22.0 ± 2.7  30.1 ± 4.8  24.0 ± 3.5  21.4 ± 1.8  21.5 ± 4.2  21.3 ± 3.2 0.0003 
Dynamic compliance, left lung, ml / cmH2O 
NS   7.8 ± 0.9 7.7 ± 1.5 7.1 ± 1.1 6.5 ± 0.9  
SF   9.8 ± 2.0 9.4 ± 1.6 9.3 ± 1.7 8.9 ± 1.1 0.031 
PaO2, mmHg 
NS 607.2 ± 35.9  569.2 ± 83.4  337.8 ± 242.5  243.4 ± 192.9  132.4 ± 95.3  64.0 ± 15.0  
SF 577.2 ± 31.7  626.0 ± 62.2  609.0 ± 78.6   574.2 ± 128.9  541.8 ± 128.8  547.8 ± 96.2 0.0022 
PaCO2, mmHg 
NS 20.9 ± 2.2  23.6 ± 2.0  33.8 ± 9.3  39.6 ± 14.8  43.0 ± 19.0  46.8 ± 17.7 
SF 20.7 ± 2.3  21.1 ± 1.7  30.3 ± 5.3  31.4 ± 6.4  34.9 ± 6.0  35.3 ± 6.2 0.27 
Mean PAP, mmHg 
NS 17.2 ± 2.6  16.8 ± 2.8  44.2 ± 16.3  43.0 ± 6.2  40.8 ± 5.1  39.0 ± 4.1 
SF 18.8 ± 2.5  17.6 ± 2.7  40.6 ± 8.8  39.8 ± 7.9  42.2 ± 6.3  41.4 ± 12.6 0.97 
Mean CVP, mmHg 
NS 4.2 ± 2.0  4.4 ± 1.7  7.2 ± 2.5  7.6 ± 1.9  9.4 ± 2.6  9.8 ± 3.8 
SF 5.6 ± 1.1  5.8 ± 1.8  7.2 ± 1.6  8.0 ± 1.7  8.0 ± 2.1  8.2 ± 2.2 0.98 
Mean LAP, mmHg 
NS 11.6 ± 2.9  8.4 ± 2.9  4.8 ± 3.3  6.2 ± 2.6  6.6 ± 2.5   7.4 ± 3.8 
SF 12.0 ± 2.9  10.8 ± 2.8  8.8 ± 1.5  9.6 ± 3.2  8.8 ± 4.1  8.2 ± 2.0 0.11 
Cardiac output, l/min 
NS 0.7 ± 0.1  0.8 ± 0.4  0.7 ± 0.1  0.7 ± 0.2  0.7 ± 0.2  0.5 ± 0.3 
SF 1.0 ± 0.2  0.8 ± 0.2  0.8 ± 0.3  0.8 ± 0.3  0.8 ± 0.2  0.9 ± 0.3 0.076 
PVR, dyn･s･cm-5 x 103 
NS 682.7 ± 334.1  994.7 ± 496.5  4813.9 ± 2124.7  4538.2 ± 1450.0  4559.4 ± 2056.5  4581.2 ± 1793.9  
SF 557.5 ± 41.2  707.6 ± 177.1  3295.9 ± 742.5  3151.5 ± 1305.9  3436.9 ± 1328.9  3049.5 ± 1031.4  0.065 
Shunt fraction, % 
NS 4.7 ± 3.3  9.5 ± 6.9  17.7 ± 12.0  29.2 ± 20.2  38.0 ± 20.9  50.5 ± 23.7 
SF 6.0 ± 2.1  4.4 ± 3.2  4.3 ± 2.8  5.7 ± 5.9  6.7 ± 4.8  7.8 ± 5.1 0.0078 
A-aDO2, mmHg 
NS 80.6 ± 36.5 115.3 ± 81.3 334.4 ± 235.9 421.9 ± 179.9 528.8 ± 80.6 592.6 ± 7.6 
SF 110.8 ± 29.7 70.6 ±41.6 78.2 ±60.1 103.2 ± 131.7 129.2 ± 133.6 122.6 ± 99.6 0.0017 
OP = operation, PAP = pulmonary artery pressure; CVP = central venous pressure; LAP = left atrial pressure; PVR = pulmonary vascular resistance; 
A-aDO2 = alveolar-arterial oxygen pressure difference. Data are shown as mean ± SD. p-values are for the differences between groups by repeated 




